Everton Rowe

1.7k total citations · 1 hit paper
26 papers, 1.2k citations indexed

About

Everton Rowe is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, Everton Rowe has authored 26 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 7 papers in Molecular Biology and 7 papers in Hematology. Recurrent topics in Everton Rowe's work include CAR-T cell therapy research (9 papers), Multiple Myeloma Research and Treatments (7 papers) and Pharmacology and Obesity Treatment (5 papers). Everton Rowe is often cited by papers focused on CAR-T cell therapy research (9 papers), Multiple Myeloma Research and Treatments (7 papers) and Pharmacology and Obesity Treatment (5 papers). Everton Rowe collaborates with scholars based in United States, Spain and France. Everton Rowe's co-authors include Ken Fujioka, Carl M. Mendel, Vanita R. Aroda, Ludger Rose, Bertrand Cariou, J. Hans DeVries, Stephen C. Bain, Mads Axelsen, Milivoj Piletič and Samuel Weinstein and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Urology.

In The Last Decade

Everton Rowe

26 papers receiving 1.1k citations

Hit Papers

Efficacy and safety of once-weekly semaglutide versus onc... 2017 2026 2020 2023 2017 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial
    2017 340 citations Vanita R. Aroda, Stephen C. Bain et al. The Lancet Diabetes & Endocrinology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Everton Rowe United States 12 731 567 386 273 199 26 1.2k
Stefan Aczél Austria 21 523 0.7× 125 0.2× 369 1.0× 198 0.7× 349 1.8× 38 1.4k
Μ. Goepel Germany 26 401 0.5× 113 0.2× 328 0.8× 99 0.4× 383 1.9× 109 2.0k
S. Strobel United States 15 1.0k 1.4× 215 0.4× 276 0.7× 275 1.0× 677 3.4× 16 1.4k
Eva W. Iepsen Denmark 13 342 0.5× 150 0.3× 346 0.9× 283 1.0× 195 1.0× 16 916
Anne M. Wolka United States 16 940 1.3× 243 0.4× 451 1.2× 144 0.5× 302 1.5× 24 1.3k
Matthew Wintle United States 12 1.4k 2.0× 308 0.5× 637 1.7× 163 0.6× 582 2.9× 18 1.6k
Maria S. Svane Denmark 21 768 1.1× 232 0.4× 295 0.8× 707 2.6× 763 3.8× 53 1.6k
Kevin Baynes United Kingdom 11 358 0.5× 113 0.2× 178 0.5× 353 1.3× 196 1.0× 23 935
I W Campbell United Kingdom 16 789 1.1× 129 0.2× 230 0.6× 250 0.9× 232 1.2× 39 1.2k
Slobodan Antić Serbia 14 859 1.2× 201 0.4× 464 1.2× 159 0.6× 295 1.5× 33 1.1k

Countries citing papers authored by Everton Rowe

Since Specialization
Citations

This map shows the geographic impact of Everton Rowe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Everton Rowe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Everton Rowe more than expected).

Fields of papers citing papers by Everton Rowe

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Everton Rowe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Everton Rowe. The network helps show where Everton Rowe may publish in the future.

Co-authorship network of co-authors of Everton Rowe

This figure shows the co-authorship network connecting the top 25 collaborators of Everton Rowe. A scholar is included among the top collaborators of Everton Rowe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Everton Rowe. Everton Rowe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Raje, Noopur, David S. Siegel, Sundar Jagannath, et al.. (2021). Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma (RRMM): Analyses of High-Risk Subgroups in the KarMMa Study. Transplantation and Cellular Therapy. 27(3). S66–S67. 2 indexed citations
4.
Berdeja, Jesús G., Noopur Raje, David S. Siegel, et al.. (2021). Efficacy and Safety of Idecabtagene Vicleucel (ide-cel, bb2121) in Elderly Patients with Relapsed and Refractory Multiple Myeloma: KarMMa Subgroup Analysis. Transplantation and Cellular Therapy. 27(3). S397–S398. 2 indexed citations
5.
Manier, Salomon, Ankit Kansagra, Larry D. Anderson, et al.. (2021). Characteristics of neurotoxicity associated with idecabtagene vicleucel (ide-cel, bb2121) in patients with relapsed and refractory multiple myeloma (RRMM) in the pivotal phase II KarMMa study.. Journal of Clinical Oncology. 39(15_suppl). 8036–8036. 4 indexed citations
6.
Kansagra, Ankit, Jesús G. Berdeja, Nina Shah, et al.. (2021). Characterization of Cytokine Release Syndrome (CRS) in the KarMMa Study of Idecabtagene Vicleucel (ide-cel, bb2121) for Relapsed and Refractory Multiple Myeloma (RRMM). Transplantation and Cellular Therapy. 27(3). S396–S397. 1 indexed citations
7.
Raje, Noopur, David S. Siegel, Sundar Jagannath, et al.. (2020). Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma: Analyses of High-Risk Subgroups in the KarMMa Study. Blood. 136(Supplement 1). 37–38. 23 indexed citations
8.
Kansagra, Ankit, Jesús G. Berdeja, Nina Shah, et al.. (2020). Characterization of Cytokine Release Syndrome in the KarMMa Study of Idecabtagene Vicleucel (ide-cel, bb2121) for Relapsed and Refractory Multiple Myeloma. Blood. 136(Supplement 1). 26–27. 15 indexed citations
9.
Jensen, Lene, Hans Helleberg, Ad F. Roffel, et al.. (2017). Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species. European Journal of Pharmaceutical Sciences. 104. 31–41. 124 indexed citations
10.
Aroda, Vanita R., Stephen C. Bain, Bertrand Cariou, et al.. (2017). Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. The Lancet Diabetes & Endocrinology. 5(5). 355–366. 340 indexed citations breakdown →
11.
Jahr, Jonathan S., et al.. (2014). The increases in potassium concentrations are greater with succinylcholine than with rocuronium-sugammadex in outpatient surgery: a randomized, multicentre trial. Canadian Journal of Anesthesia/Journal canadien d anesthésie. 61(5). 423–432. 10 indexed citations
12.
Hosgood, Giselle, et al.. (2010). Evaluation of intra-articular and subcutaneous administration of meloxicam for postoperative analgesia following stifle surgery in dogs. Veterinary and Comparative Orthopaedics and Traumatology. 24(1). 32–38. 8 indexed citations
13.
14.
McMahon, F. Gilbert, et al.. (2002). Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. Journal of Human Hypertension. 16(1). 5–11. 73 indexed citations
15.
Sramek, John J., Mark Leibowitz, Samuel Weinstein, et al.. (2002). Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by β-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial. Journal of Human Hypertension. 16(1). 13–19. 43 indexed citations
16.
17.
Fujioka, Ken, T. B. Seaton, Everton Rowe, et al.. (2000). Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obesity and Metabolism. 2(3). 175–187. 175 indexed citations
18.
McMahon, F. Gilbert, Ken Fujioka, Bramah N. Singh, et al.. (2000). Efficacy and Safety of Sibutramine in Obese White and African American Patients With Hypertension. Archives of Internal Medicine. 160(14). 2185–2185. 184 indexed citations
19.
Patel, H. I. & Everton Rowe. (1999). SAMPLE SIZE FOR COMPARING LINEAR GROWTH CURVES. Journal of Biopharmaceutical Statistics. 9(2). 339–350. 13 indexed citations
20.
WIENER, ISIDORO, et al.. (1986). Colitis CyStica Profunda. Southern Medical Journal. 79(9). 1167–1169. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Stefan Aczél Breakdown of academic impact, for papers by Μ. Goepel Breakdown of academic impact, for papers by S. Strobel Breakdown of academic impact, for papers by Eva W. Iepsen Breakdown of academic impact, for papers by Anne M. Wolka Breakdown of academic impact, for papers by Matthew Wintle Breakdown of academic impact, for papers by Maria S. Svane Breakdown of academic impact, for papers by Kevin Baynes Breakdown of academic impact, for papers by I W Campbell Breakdown of academic impact, for papers by Slobodan Antić
Rankless by CCL
2026